Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSEMKT:PLX
- CUSIP: N/A
- Web: N/A
- Market Cap: $102.46 million
- Outstanding Shares: 126,499,000
- 50 Day Moving Avg: $0.87
- 200 Day Moving Avg: $0.84
- 52 Week Range: $0.26 - $1.51
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.36
- P/E Growth: -0.100
- Annual Revenue: $11.41 million
- Price / Sales: 8.98
- Book Value: ($0.55) per share
- Price / Book: -1.47
- Average Volume: 1.85 million shs.
- Beta: 0.95
- Short Ratio: 3.18
Frequently Asked Questions for Protalix Biotherapeutics (NYSEMKT:PLX)
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. The company had revenue of $2.89 million for the quarter, compared to analyst estimates of $2.55 million. During the same period last year, the firm earned ($0.09) earnings per share. View Protalix Biotherapeutics' Earnings History.
Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?
3 brokerages have issued 1 year price objectives for Protalix Biotherapeutics' shares. Their forecasts range from $0.80 to $5.00. On average, they expect Protalix Biotherapeutics' stock price to reach $2.27 in the next twelve months. View Analyst Ratings for Protalix Biotherapeutics.
Who are some of Protalix Biotherapeutics' key competitors?
Some companies that are related to Protalix Biotherapeutics include Immune Design Corp. (IMDZ), DURECT Corporation (DRRX), Protagonist Therapeutics (PTGX), NewLink Genetics Corporation (NLNK), Abeona Therapeutics (ABEO), Signal Genetics (MGEN), Arbutus Biopharma Corporation (ABUS), Senseonics Holdings (SENS), Pieris Pharmaceuticals (PIRS), Urogen Pharma (URGN), Enzymotec (ENZY), Novelion Therapeutics (NVLN), Compugen (CGEN), OBALON THERPTCS (OBLN), Viralytics (VRACY), Neos Therapeutics (NEOS), ConforMIS (CFMS) and Pharming Group (PHGUF).
Who owns Protalix Biotherapeutics stock?
Protalix Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.00%), California Public Employees Retirement System (0.00%), Jane Street Group LLC (0.15%) and Wells Fargo & Company MN (0.08%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc, Moshe Manor and Yossi Maimon. View Institutional Ownership Trends for Protalix Biotherapeutics.
Who sold Protalix Biotherapeutics stock? Who is selling Protalix Biotherapeutics stock?
Who bought Protalix Biotherapeutics stock? Who is buying Protalix Biotherapeutics stock?
Protalix Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Wells Fargo & Company MN. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Camber Capital Management Llc, Moshe Manor and Yossi Maimon. View Insider Buying and Selling for Protalix Biotherapeutics.
How do I buy Protalix Biotherapeutics stock?
Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
MarketBeat Community Rating for Protalix Biotherapeutics (NYSEMKT PLX)MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Protalix Biotherapeutics stock can currently be purchased for approximately $0.81.
Consensus Ratings for Protalix Biotherapeutics (NYSEMKT:PLX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$2.27|
Analysts' Ratings History for Protalix Biotherapeutics (NYSEMKT:PLX)
(Data available from 6/22/2015 forward)
|5/23/2017||Rodman & Renshaw||Reiterated Rating||Buy||$5.00|
|9/6/2016||Jefferies Group LLC||Lower Price Target||Buy||$1.75 -> $0.80|
Earnings History for Protalix Biotherapeutics (NYSEMKT:PLX)Earnings History by Quarter for Protalix Biotherapeutics (NYSEMKT PLX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q1 17||($0.09)||($0.07)||$2.55 million||$2.89 million||View||N/A|
|8/8/2016||Q2 16||($0.08)||($0.11)||$1.34 million||$1.77 million||View||N/A|
|3/8/2016||Q415||($0.29)||$3.50 million||$4.40 million||View||N/A|
|11/9/2015||Q3 15||($0.08)||($0.04)||$5.00 million||$4.30 million||View||N/A|
|8/10/2015||Q215||($0.08)||($0.05)||$6.40 million||$3.78 million||View||N/A|
|5/7/2015||Q1 15||($0.08)||($0.06)||$8.20 million||$4.39 million||View||N/A|
|8/7/2014||($0.07)||($0.07)||$9.63 million||$2.43 million||View||N/A|
|5/8/2014||($0.07)||($0.08)||$8.25 million||$6.70 million||View||N/A|
|3/13/2014||Q413||($0.02)||($0.12)||$5.54 million||$2.36 million||View||N/A|
Earnings Estimates for Protalix Biotherapeutics (NYSEMKT:PLX)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.11 EPS
Dividend History for Protalix Biotherapeutics (NYSEMKT:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Protalix Biotherapeutics (NYSEMKT:PLX)Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/16/2017||Moshe Manor||CEO||Buy||50,000||$0.81||$40,500.00|| |
|12/2/2016||Camber Capital Management Llc||Major Shareholder||Sell||2,500,000||$0.32||$800,000.00|| |
|12/14/2015||Yossi Maimon||CFO||Buy||10,000||$0.78||$7,800.00|| |
|10/19/2015||Camber Capital Management Llc||Major Shareholder||Buy||4,000,423||$1.00||$4,000,423.00|| |
|8/15/2013||Alfred Akirov||Director||Sell||112,330||$5.05||$567,266.50|| |
Headline Trends for Protalix Biotherapeutics (NYSEMKT:PLX)
Latest Headlines for Protalix Biotherapeutics (NYSEMKT:PLX)
|Protalix BioTherapeutics (PLX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow|
seekingalpha.com - June 8 at 8:08 PM
|Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility|
finance.yahoo.com - June 1 at 8:06 PM
|Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock? - Nasdaq|
www.nasdaq.com - May 31 at 1:07 PM
|Rodman & Renshaw Reaffirms "Buy" Rating for Protalix Biotherapeutics Inc (PLX)|
www.americanbankingnews.com - May 27 at 11:16 PM
|Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - May 27 at 2:30 AM
|Protalix BioTherapeutics (PLX) Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in CF - StreetInsider.com|
www.streetinsider.com - May 25 at 12:35 AM
|Protalix Biotherapeutics Inc (PLX) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - May 17 at 7:52 AM
|Protalix Biotherapeutics Inc (PLX) CEO Moshe Manor Acquires 50,000 Shares|
www.americanbankingnews.com - May 16 at 1:20 PM
|Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017|
finance.yahoo.com - May 12 at 8:02 PM
|Protalix Biotherapeutics Inc (PLX) Issues Earnings Results|
www.americanbankingnews.com - May 11 at 2:46 PM
|Edited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT|
finance.yahoo.com - May 11 at 8:40 AM
|Protalix Biotherapeutics (PLX) Earning Somewhat Positive Media Coverage, Study Shows|
www.americanbankingnews.com - May 9 at 12:51 AM
|Protalix Biotherapeutics (PLX) Receives Daily Media Sentiment Score of 0.34|
www.americanbankingnews.com - May 5 at 10:14 PM
|Protalix BioTherapeutics Is Positioned Well For The Future|
seekingalpha.com - April 21 at 12:23 AM
|Protalix BioTherapeutics (PLX) Announces New Data Demonstrating Positive Effect of PRX-102 - StreetInsider.com|
www.streetinsider.com - April 19 at 9:51 AM
|Protalix BioTherapeutics Announces New Preclinical Results ... - Yahoo Finance|
finance.yahoo.com - April 18 at 6:35 PM
|Protalix Biotherapeutics (PLX) Earns Coverage Optimism Score of 0.57|
www.americanbankingnews.com - April 17 at 10:31 AM
|Rodman & Renshaw Increases Protalix Biotherapeutics Inc (PLX) Price Target to $5.00|
www.americanbankingnews.com - April 17 at 9:18 AM
|Protalix BioTherapeutics: The DNase Treatment For Cystic Fibrosis And Opportunity For Profits - Seeking Alpha|
seekingalpha.com - April 14 at 6:57 AM
|AERI's Rocket Hits Target, ENTL Gets FDA Nod, NOVN Jumps On Positive Trial Data|
www.rttnews.com - April 13 at 9:30 AM
|Protalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF|
www.streetinsider.com - April 13 at 9:30 AM
|Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials|
finance.yahoo.com - April 13 at 9:30 AM
|Protalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF - StreetInsider.com|
www.streetinsider.com - April 12 at 11:56 PM
|Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis|
finance.yahoo.com - April 12 at 1:50 PM
|Do Options Traders Know Something About Protalix (PLX) Stock We Don't?|
finance.yahoo.com - April 7 at 11:56 AM
|Protalix BioTherapeutics Looks Solid With Strong Pipeline - Protalix ... - Seeking Alpha|
seekingalpha.com - March 27 at 6:43 PM
|Protalix Biotherapeutics Inc (PLX) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 22 at 6:01 PM
|Protalix BioTherapeutics: Exploring Ulcerative Colitis - Seeking Alpha|
seekingalpha.com - March 16 at 8:31 AM
|Q4 2016 Protalix Biotherapeutics Inc Earnings Release - Time Not Supplied|
biz.yahoo.com - March 16 at 8:31 AM
|Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update|
finance.yahoo.com - March 16 at 8:31 AM
|PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition|
biz.yahoo.com - March 16 at 8:31 AM
|Protalix Biotherapeutics Inc (PLX) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - March 15 at 8:19 AM
|Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16 ... - GlobeNewswire (press release)|
globenewswire.com - March 9 at 7:06 PM
|Technical Reports on Biotech Stocks -- Juno Therapeutics, Protalix BioTherapeutics, ImmunoGen, and ContraVir Pharma|
www.bizjournals.com - February 23 at 8:58 AM
|Protalix BioTherapeutics: New Institutional Ownership Swells Ahead Of Major Catalysts|
seekingalpha.com - February 21 at 5:35 PM
|PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure|
biz.yahoo.com - February 16 at 6:52 PM
|Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders|
us.rd.yahoo.com - February 14 at 11:33 PM
|Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)|
globenewswire.com - February 14 at 11:33 PM
|Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017 - GlobeNewswire (press release)|
www.globenewswire.com - February 14 at 4:21 AM
|Protalix continues up move, shares ahead 27% - Seeking Alpha|
seekingalpha.com - February 14 at 4:21 AM
|Gainers & Losers Of The Day: ZSAN, PLSE, XOMA, SAGE, CBIO...|
www.finanznachrichten.de - February 13 at 11:19 PM
|Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017|
us.rd.yahoo.com - February 13 at 11:19 PM
|8:42 am Protalix BioTherapeutics outperforming ahead of the open after previewing its presentations at this week's Annual WORLDSymposium (2/13-2/17)|
us.rd.yahoo.com - February 13 at 11:19 PM
|Protalix BioTherapeutics to Participate in the 13th Annual ... - GlobeNewswire (press release)|
globenewswire.com - February 13 at 9:14 AM
|Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%|
www.zacks.com - January 30 at 8:28 AM
|Knight Therapeutics Acquires 6.2M Shares of Protalix ... - StreetInsider.com|
www.streetinsider.com - January 30 at 12:44 AM